(S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-cyclohexyl-benzyl ester | 702681-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-3-[3-(1-carboxy-1-methyl-ethoxy)-phenyl]-piperidine-1-carboxylic acid 4-cyclohexyl-benzyl ester
• 英文别名: 2-[3-[(3S)-1-[(4-cyclohexylphenyl)methoxycarbonyl]piperidin-3-yl]phenoxy]-2-methylpropanoic acid
• CAS: 702681-70-7
• 化学式: C₂₉H₃₇NO₅
• 分子量: 479.616
• InChiKey: HOJOTYJFNLOVSV-RUZDIDTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PPAR activators
  申请人：Pfizer Inc

  公开号：US20040157885A1

  公开（公告）日：2004-08-12

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPAR alpha激动剂，含有这些化合物的药物组合物以及使用这些化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇并降低其他某些血浆脂质水平，例如低密度脂蛋白胆固醇和甘油三酯，并因此治疗由低HDL胆固醇水平和/或高LDL胆固醇和甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。
• PPAR ACTIVATORS
  申请人：Bagley W. Scott

  公开号：US20070191429A1

  公开（公告）日：2007-08-16

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPAR alpha激动剂，含有这种化合物的制药组合物以及使用这种化合物提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和三酰甘油，因此治疗低密度脂蛋白胆固醇和/或高三酰甘油水平加重的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中使用。
• PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS
  申请人：Pfizer Products Inc.

  公开号：EP1567493B1

  公开（公告）日：2009-03-18
• USE OF PPAR AGONISTS TO TREAT RUMINANTS
  申请人：Pfizer Products Incorporated

  公开号：EP1765320A2

  公开（公告）日：2007-03-28
• Use
  申请人：Kehrli Eugene Marcus

  公开号：US20070281935A1

  公开（公告）日：2007-12-06

  The use of a compound of formula I: an isomer thereof, a prodrug of said compound or isomer, or a pharmaceutically acceptable salt of said compound, isomer or prodrug, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of negative energy balance in ruminants. The use of a compound of formula 1, in the manufacture of a medicament for the palliative, prophylactic or curative treatment of ruminant disease associated with negative energy balance in ruminants, wherein, preferably, the ruminant disease associated with negative energy balance in ruminants is selected from fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)-metritis, infertility, low fertility, and lameness.